An observational study investigating the effectiveness, safety, and costs of switching to dual therapy with dolutegravir plus rilpivirine in treatment-experienced patients with HIV infections.

Trial Profile

An observational study investigating the effectiveness, safety, and costs of switching to dual therapy with dolutegravir plus rilpivirine in treatment-experienced patients with HIV infections.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Rilpivirine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2017 New trial record
    • 01 Aug 2017 Results published in the Annals of Pharmacotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top